PET scans are often used in the management of patients with Hodgkin and non-Hodgkin lymphoma. They are often valuable for the staging, assessment of response to therapy, and surveillance for recurrent disease in patients who have completed treatment. However, false positive findings after therapy are not uncommon and may lead to additional testing. This presentation reviewed current indications for PET scans in patients with lymphoma and provided an overview of the PET Harmonization Project.
Barry L. Shulkin, MD, MBA
Chief, Division of Nuclear Medicine
St. Jude Children’s Research Hospital, Memphis